Merck launches new membrane plant in Ireland, opening new jobs

Satellite image of Ireland
Ireland

Merck ($MRK) recently unveiled a new manufacturing and R&D facility in Carrigtwohill, County Cork, Ireland that represents a $62 million investment and the creation of up to 70 new positions. 

The specialty membrane facility will take over all development of membrane work for the German drug company in the wake of the closing of a plant in the U.S.,” Martin McAuliffe, the company’s site leader, told the Irish Times.

“We are adding R&D capability to develop and scale up,” he said. “We also do antibody development onsite.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Merck didn’t respond to a FiercePharmaManufacturing request about details concerning the closure of the U.S. plant.

McAuliffe added that the small number of R&D employees at the facility now will “grow substantially” in the next few years. There are currently about 700 staff at the Cork site. 

“In the past, scale-up and development of new membranes would be done in the U.S.,” he said. “We have a facility there that’s closing at the end of the year.”

The recent expansions by Merck in Ireland stand in stark contrast to the deep cuts the company made three years ago when it closed a plant in Rathdrum and trimmed jobs at its API plant in Brinny.

- here’s the Irish Times story

Read more on

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.